biotech / news / / Seeking Alpha
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod.
Roche is initiating a new Phase 3 trial for Elevidys targeting Duchenne muscular dystrophy.
KEY POINTS
- The new trial aims specifically to support Elevidys approval in the European Union.
- Elevidys was developed through collaboration between Roche and Sarepta Therapeutics.
- Prior data was insufficient for EU approval, prompting this additional late-stage trial.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →